Eagle Bulk Shipping (EGLE) – Quarterly Results In Line With Expectations

Monday, May 09, 2022

Eagle Bulk Shipping (EGLE)
Quarterly Results In Line With Expectations

Eagle Bulk Shipping Inc. (“Eagle”) is a US-based drybulk owner-operator focused on the Supramax/Ultramax mid-size asset class, which ranges from 50,000 and 65,000 deadweight tons in size; these vessels are equipped with onboard cranes allowing for the self-loading and unloading of cargoes, a feature which distinguishes them from the larger classes of drybulk vessels and provides for greatly enhanced flexibility and versatility- both with respect to cargo diversity and port accessibility. The Company transports a broad range of major and minor bulk cargoes around the world, including coal, grain, ore, pet coke, cement, and fertilizer. Eagle operates out of three offices, Stamford (headquarters), Singapore, and Hamburg, and performs all aspects of vessel management in-house including: commercial, operational, technical, and strategic.

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Eagle Bulk Shipping reported 2022-1Q results generally in line with expectations. Revenues, net were $184.4 million versus $93.4 million for the same period last year and in line with our $182.4 million estimate. Adjusted EBITDA (excluding unrealized derivative value changes) was $85.0 million versus our $88.1 million estimate. Adjusted net income was $64.5 million ($3.97 per diluted share) versus $9.3 million ($0.80) last year and in line with our estimate of $64.3 million ($4.00). The consensus analyst estimate was $3.97.

Charter rates are high. The company achieved a TCE rate of $27,407/day in the quarter, benefitting from a sharp run up in shipping rates last fall. Eagle is well protected against any decline in rates having locked in 83% of available days fixed at an average TCE rate of $29,300. CEO Gary Vogel indicated that “the demand growth for minor bulks remains healthy and continues to outpace demand for the broader drybulk market.” Disruptions caused by the war in Ukraine have resulted in longer voyage distances and higher rates….

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Gray Television (GTN) – Plowing Through The Noise

Monday, May 09, 2022

Gray Television (GTN)
Plowing Through The Noise

Gray Television is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets in the United States. Our television stations serve 113 television markets that collectively reach approximately 36 percent of US television households. This portfolio includes 80 markets with the top-rated television station and 100 markets with the first and/or second highest rated television station. We also own video program companies Raycom Sports, Tupelo Honey, PowerNation Studios and Third Rail Studios.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Exceeds expectations. The company blew through our revenue and adj. EBITDA estimates in its first quarter. Revenues increased a strong 9.8% to $827.0 million, nicely above our $793.0 million estimate, and above its previous guidance. Adj. EBITDA was a solid $251.0 million, up 8.2%, and above our $212.0 million estimate. 

Core and Retransmission revenue trends favorable. The Q1 upside revenue variance was driven by better than expected Core advertising (up 4% versus guidance of 3% to 5%) and better Retransmission revenue, in part related to a true-up. The company expects solid Retrans revenue of $385 million to $390 million in Q2, better than our original estimate. Management indicated that subscriber counts appear stable. …

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Ocugen (OCGN) – First Quarter Reported With Gene Therapy Programs Making Progress

Monday, May 09, 2022

Ocugen (OCGN)
First Quarter Reported With Gene Therapy Programs Making Progress

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Ocugen Reports 1Q22 Within Expectations.   Ocugen reported a loss of $18.0 million or $(0.09) per share, larger than our expected loss of $15.8 million or $(0.06) per share.  During the quarter, the company continued to work with US and Canadian regulators toward Covaxin approval.  The Phase 1/2 OCU400 gene therapy trial continues to enroll patients.  Cash balance at the end of 1Q was $129.9 million.

Ocugen Continues To Work Toward Covaxin Approval.  The US bioequivalence Phase 2/3 immuno-bridging study stopped new enrollment due to undisclosed issues at Bharat Biotech’s manufacturing plant.  As these issues are being addressed, the company continues to speak with the FDA to lift the clinical hold and to determine requirements for the BLA submission….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kratos Defense & Security (KTOS) – A CR Impacted Quarter, but Future is Brighter

Monday, May 09, 2022

Kratos Defense & Security (KTOS)
A CR Impacted Quarter, but Future is Brighter

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms, and systems for United States National Security related customers, allies, and commercial enterprises. Kratos is changing the way breakthrough technologies for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research, and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training and combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.kratosdefense.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q22 Results. Revenue of $196.2 million, up 1.0% y-o-y, and came in at the mid-point of the $190-$200 million guidance. Revenue from acquisitions offset CR related impacts and the decline in the Training business. Adjusted EBITDA came in at $13.8 million, above guidance, versus $18.1 million a year ago. GAAP EPS loss was $0.12, adjusted EPS net income was $0.04.

Brighter Days? With the Continuing Resolution behind us, it appears there is a high potential for new awards. On the call, CEO DeMarco stated “We have now received or have been informed that we will receive several large new contracts in our unmanned systems and our satellite business, including our new software based OpenSpace products.”…

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights



Tonix Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

Research, News, and Market Data on Tonix Pharmaceuticals

Fibromyalgia Phase 3
Trial of TNX-102 SL Enrollment Initiated; Results from Interim Analysis
Expected First Quarter 2023

Long COVID IND Cleared
for TNX-102 SL; Phase 2 Trial Expected to Initiate Second Quarter 2022

Three Additional CNS
Programs Expected to Initiate Phase 2 Studies in 2022: TNX-1300 for Cocaine
Intoxication, TNX-1900 for Chronic Migraine and TNX-102 SL for PTSD

FDA Granted Orphan-Drug
Designation for TNX-2900 for Treatment of Prader-Willi Syndrome

Organ Transplantation
Phase 1 Study of TNX-1500 Expected to Initiate Second Half 2022

Cash and Cash Equivalents
Totaled Approximately $140 Million at March 31, 2022

CHATHAM, N.J., May 09, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022, and provided an overview of recent operational highlights.

“Tonix is making meaningful strides developing our rich portfolio of high impact product candidates,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “By the end of this year, we expect to have five central nervous system (CNS) programs in the clinic, led by our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development. Enrollment has begun for TNX-102 SL in a registration-enabling-Phase 3 clinical trial. TNX-102 SL trials in Long COVID and PTSD are also expected to initiate enrollment in the second quarter of 2022.”

Dr. Lederman continued, “Long COVID is a growing problem because it is a chronic condition experienced by approximately 30% of people who recover from COVID-19. There is no currently approved treatment for this condition. We recently reported data from a retrospective observational study of U.S. adults that shows that 35% of Long COVID sufferers who experience multi-site pain are turning to addictive opioids. We are excited to study TNX-102 SL for this condition, since TNX-102 SL is a centrally-acting, non-addictive analgesic which is intended for chronic use. We look forward to starting our Phase 2 study for Long COVID with multi-site pain imminently.”

Gregory Sullivan, M.D., Chief Medical Officer of Tonix said, “We are excited by the opportunities ahead for our rich pipeline of CNS, rare disease, immunology and infectious disease product candidates. TNX-1300 (recombinant double mutant cocaine esterase) is expected to start enrolling in a Phase 2 trial in the second quarter of 2022 for emergency department treatment of cocaine intoxication, and TNX-1900 (intranasal potentiated oxytocin) is expected to enter the clinic in the second half of 2022 for the prevention of migraines in chronic migraineurs. In addition to the CNS programs, we expect to begin a Phase 1 study of TNX-1500, a monoclonal antibody targeting CD40 ligand, also known as CD154, which will initially be developed to prevent organ transplant rejection and, ultimately, to treat autoimmune conditions. We continue to progress our infectious disease portfolio, which is led by our smallpox vaccine, TNX-801 (live horsepox virus vaccine). We are also developing the live-virus vectored COVID-19 vaccines, TNX-1840 and TNX-1850 that are designed to express the spike proteins from the omicron and BA.2 variants, respectively.”

Recent Highlights—Key
Product Candidates*

Central Nervous System (CNS) Pipeline

TNX-102 SL (cyclobenzaprine HCl sublingual
tablet): small molecule for the management of fibromyalgia (FM)

  • In April 2022, Tonix initiated enrollment in the RESILIENT study, a double-blind, randomized, placebo-controlled, potentially pivotal Phase 3 study of TNX-102 SL for the management of fibromyalgia. The two-arm trial is expected to enroll approximately 470 participants in the U.S. Results from a planned interim analysis are expected first quarter 2023.
  • In March 2022, Tonix reported topline data from its second Phase 3 study, RALLY. As expected, based on interim analysis results reported in July 2021, TNX-102 SL did not achieve statistical significance over placebo on the primary endpoint of reduction in daily pain (p=0.115). Tonix reported the interim analysis of RALLY in July 2021 in which the independent data monitoring committee recommended stopping the study for futility. The Company therefore stopped enrollment of new participants while continuing those participating at that time to completion. Topline data revealed that an unexpected number of adverse event related discontinuations in both drug and placebo treated groups may have contributed to the statistical miss.
  • Tonix reported positive results on the primary endpoint of reduction in daily pain (p=0.010) from the Phase 3 RELIEF study for the management of fibromyalgia in December 2020.

TNX-102 SL for the treatment of Long COVID,
also known as Post-Acute Sequelae of COVID-19 (PASC)

  • In April 2022, Tonix announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application to support a Phase 2 clinical study with TNX-102 SL as a potential treatment for a subset of patients with Long COVID with multi-site pain and will utilize a daily pain diary as the primary endpoint. The Phase 2 trial is expected to start second quarter 2022.
  • In April 2022, Tonix announced results of a retrospective observational database study of over 50,000 adult U.S. patients with Long COVID. Results showed that over 40% of patients had fibromyalgia-like multi-site pain. These findings support the feasibility of the planned Phase 2 study which will enroll Long COVID patients with multi-site pain.
  • The retrospective observational database study also revealed a high rate of opioid use in Long COVID patients with multi-site pain. These findings raise concerns about development of opioid use disorder in Long COVID patients who find nowhere else to turn for symptom relief, adding to an existing national health crisis resulting from chronic use of opioids.

TNX-102 SL for the treatment of Posttraumatic
Stress Disorder (PTSD)

  • Tonix expects to begin enrolling a Phase 2 study of TNX-102 SL in police in Kenya in the second quarter of 2022. The new PTSD study will use one month look-back CAPS-5 as the primary endpoint rather than one week look-back as was used in prior studies after a clinical guidance meeting with the FDA.

TNX-1300 (recombinant double mutant cocaine
esterase): biologic for life-threatening cocaine intoxication

  • Tonix expects to initiate a Phase 2 open-label safety study of TNX-1300 in an emergency department setting in the second quarter of 2022. TNX-1300 was licensed from Columbia University. A positive Phase 2a study of volunteer cocaine users in a controlled laboratory setting has been previously completed. TNX-1300 has been granted Breakthrough Therapy designation by the FDA.

TNX-1900 (intranasal potentiated oxytocin):
small peptide for migraine, craniofacial pain, insulin resistance and related
disorders, and binge eating disorder

  • In late 2021, Tonix received IND clearance from the FDA to support the initiation of a Phase 2 study of TNX-1900 for the prevention of migraine headache in chronic migraineurs. The 505(b)(2) pathway for FDA approval is expected to be acceptable for this program since intravenous oxytocin is FDA approved and widely used to induce labor in pregnancy. The Company continues to expect to begin enrollment in the second half of 2022.
  • In March 2022, Tonix entered into an agreement with Massachusetts General Hospital to evaluate TNX-1900 in an investigator-initiated Phase 2 clinical trial as a potential treatment for binge eating disorder. The Phase 2 clinical trial is expected to start in the second half of 2022.
  • Tonix’s proprietary formulation includes magnesium (Mg), which has been reported to potentiate the binding of oxytocin to the oxytocin receptor. Further evidence for the role of Mg in potentiating the effects of oxytocin at the oxytocin receptor were published by a third party
    1.

TNX-601 CR (tianeptine oxalate and naloxone
controlled-release tablets): small molecule for the treatment of major
depressive disorder, PTSD and neurocognitive dysfunction associated with
corticosteroid use.

  • Based on official minutes from a pre-IND meeting with the FDA, the Company expects to initiate a Phase 2 study for the treatment of major depressive disorder (depression) in the first quarter of 2023. Tonix previously completed a Phase 1 trial for formulation development outside of the U.S.

Rare Disease Pipeline

TNX-2900 (intranasal potentiated oxytocin):
small peptide for the treatment of Prader-Willi syndrome (PWS)

  • TNX-2900 received Orphan-Drug designation by the FDA for the treatment of PWS in March 2022.
  • In February 2022, Tonix entered into a sponsored research agreement with Inserm (the French National Institute of Health and Medical Research) and Aix-Marseille Université to study oxytocin in the genetically engineered mouse model of Prader-Willi syndrome, a rare genetic disorder that causes distinct, but related pathological eating disorders in newborns versus adolescents and young adults.

Immunology Pipeline

TNX-1500 (anti-CD40L monoclonal antibody):
third generation monoclonal antibody for prophylaxis of organ transplant
rejection and treatment of autoimmune disorders.

  • Tonix expects to start a Phase 1 study in the second half of 2022. Preliminary results from ongoing experiments in heart and kidney transplants in non-human primates at Massachusetts General Hospital indicate that TNX-1500 appears to have monotherapy efficacy in promoting rejection-free transplant organ acceptance and no evidence of thrombosis, a serious safety concern that was present in earlier generations of anti-CD40L antibodies, has been observed.

Infectious Disease Pipeline

TNX-801 (live horsepox virus vaccine for
percutaneous administration): vaccine against smallpox and monkeypox designed
as a single-administration vaccine to elicit T cell immunity

  • Tonix previously reported protection of non-human primates from a monkeypox challenge2. TNX-801 is less virulent than traditional vaccinia vaccines in mice.3

TNX-1840 /-1850 (live virus vaccines based on
Tonix’s recombinant pox virus vector): COVID-19 vaccines designed as
single-administration vaccines to elicit T cell immunity

  • Because the omicron and BA.2 variants have out-competed the ancestral Wuhan strain, Tonix is now planning new versions of the TNX-1800 vaccine: TNX-1840 and TNX-1850, that are designed to express spike protein from the omicron and BA.2 variants, respectively. TNX-1840 and TNX-1850 are next-generation COVID-19 vaccines using live virus technology designed to primarily elicit a T cell response believed to result in longer durability of protection and to potentially block forward transmission.

TNX-3700: COVID-19 mRNA vaccine candidate
using a zinc nanoparticle (ZNP) formulation

  • In January 2022, Tonix entered into an exclusive option and research collaboration with Kansas State University (K-State) to develop ZNP mRNA vaccines that replace the lipid nanoparticle (LNP) technology in current mRNA COVID-19 vaccines. The new ZNP technology has the potential to confer increased stability to mRNA vaccines over a wide range of temperatures, addressing limits to rapid global deployment.

TNX-2300: Live virus vaccine based on a bovine
parainfluenza virus vector to protect against COVID-19

  • In April 2022, Tonix announced a new preclinical research agreement with K-State to develop a vaccine candidate, TNX-2300, for the prevention of COVID-19 that utilizes a novel live virus vaccine vector platform. The candidate will also test the efficacy of co-expression of the CD40-ligand to stimulate T cell immunity.
  • TNX-2300 is designed to potentially stimulate immunity against the SARS-CoV-2 spike protein. The research is being directed by Dr. Waithaka Mwangi, Kansas State University, Department of Diagnostic Medicine/Pathobiology, who is the inventor of the new technology. In addition, K-State has granted Tonix an option for an exclusive license for the clinical and commercial use of K-State’s intellectual property associated with coronavirus vaccines under this relationship.

TNX-2100 (diagnostic skin test): SARS-CoV-2
epitope peptide mixtures for intradermal administration to measure the
delayed-type hypersensitivity (DTH) reaction to SARS-CoV-2

  • Tonix initiated enrollment in a dose-finding clinical study for TNX-2100 in early January 2022. However, due to the current COVID landscape in which the U.S. Centers for Disease Control and Prevention (CDC) reports4 that approximately 60% of adults and approximately 75% of children and adolescents in the U.S. have been infected with SARS-CoV-2, and the current U.S. strategy of reducing or eliminating control measures such as mask-mandates, lockdowns or surveillance, Tonix has stopped enrollment in the study and is terminating further development in the U.S.

      *All of
Tonix’s product candidates are investigational new drugs or biologics and have
not been approved for any indication.

1Meyerowitz, J.G.,
Robertson, M.J., Barros-Álvarez, X. et al. The oxytocin signaling
complex reveals a molecular switch for cation dependence. Nat Struct Mol
Biol (2022). 
https://doi.org/10.1038/s41594-022-00728-4
2Noyce, RS, et al. Synthetic Chimeric Horsepox
Virus (scHPXV) Vaccination Protects Macaques from Monkeypox* Presented as a
poster at the American Society of Microbiology BioThreats Conference
– January 29, 2020, Arlington, VA.
 (https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf )
3Noyce RS, et al. Construction of an infectious
horsepox virus vaccine from chemically synthesized DNA fragments.
 PLoS One.
2018 Jan 19;13(1): e0188453.

4Clarke KE, et al. Seroprevalence of Infection-Induced
SARS-CoV-2 Antibodies — United States, September 2021–February 2022.
MMWR Morb Mortal Wkly Rep 2022;71:606-608.
DOI: http://dx.doi.org/10.15585/mmwr.mm7117e3

Recent
Highlights–Financial

As of March 31, 2022, Tonix had $140.4 million of cash and cash equivalents, compared to $178.7 million as of December 31, 2021. Subsequent to March 31, 2022, the Company sold 33.9 million shares of common stock in at-the-market offerings (ATM) sales under a Sales Agreement with A.G.P./Alliance Global Partners, for net proceeds of approximately $6.8 million. Additionally, the Company sold 13.0 million shares of common stock under the Purchase Agreement with Lincoln Park for net proceeds of approximately $2.0 million.

Cash used in operations was approximately $31.1 million for the first quarter ended March 31, 2022, compared to $21.1 million for the first quarter ended March 31, 2021. The increase in primarily due to an increase in research and development (R&D) expense, general and administrative (G&A) expense, and increases in working capital. Capital expenditures were approximately $20.2 million for the first quarter ending March 31, 2022 compared to $0.5 million for the first quarter ended March 31, 2021. The increase was primarily due to the continued buildout of the Advanced Development Center in North Dartmouth, Mass.

First Quarter 2022 Financial Results

R&D expenses for the first quarter of 2022 were $18.4 million, compared to $15.3 million for the same period in 2021. This increase is predominately due to employee-related expenses and non-clinical expenses. We continue to expect R&D expenses to increase during 2022 as we move our clinical development programs forward and invest in our development pipeline.

G&A expenses for the first quarter of 2022 were $8.0 million, compared to $5.4 million for the same period in 2021. The increase is primarily due to employee-related expenses.

Net loss per common share was $26.4 million, or $0.05 per share, basic and diluted, for the first quarter of 2022, compared to net loss of $20.7 million, or $0.07 per share, basic and diluted, for the first quarter of 2021. The basic and diluted weighted average common shares outstanding for the first quarter of 2022 was 522,060,899, compared to 290,106,510 shares for the first quarter of 2021.

About Tonix Pharmaceuticals Holding Corp.1

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA. Finally, TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the second half of 2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox called TNX-801, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-1850, which are live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform.

1All of Tonix’s product candidates are
investigational new drugs or biologics and have not been approved for any
indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

TONIX PHARMACEUTICALS HOLDING CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Share and Per Share Amounts)
(unaudited)


TONIX PHARMACEUTICALS HOLDING CORP.

CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands)
(Unaudited)

1The condensed consolidated balance sheet for the year ended December 31, 2021 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com

(862) 799-8599

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com

(646) 942-5588

Peter Vozzo (investors)
ICR Westwicke
peter.vozzo@westwicke.com

(443) 213-0505

 

Source: Tonix Pharmaceuticals Holding Corp.

Twitter is about to Make Stock Market History with $RICK


Image Credit: Bombshells (Property of RCI Holdings)


Twitter and Ricks Hospitality Will Make History After the Closing Bell May 9

Twitter Spaces or just Spaces when on Twitter ($TWTR) is a relatively new way to hold a live audio conversation on Twitter between two parties, groups, or in a meeting setting. An earnings call, for public companies is a quarterly check-in with investors, analysts, and the media to discuss the company’s financial results for the prior reporting period.  On Monday, May 9th, at 4:30 PM ET, RCI Hospitality will hold its earnings call on Twitter Spaces. This event will make them the first in what may soon become the norm for corporations.

You can be part of history by logging in on Twitter’s audio platform to this reporting event.  

 

About RCI Hospitality, Holdings (RICK)

RCI owns and operates upscale gentlemen’s clubs and restaurants. Additionally, there is a website and media division. The banner below gives a great visual cross-section of their properties.


Image: Twitter @RicksCEO

If you want to explore Twitter Spaces, or learn about RICKs earnings, or just be part of history, here are the details of how to participate:

  • To participate in the RCI 2Q22 Earnings Call Twitter Space, follow @RicksCEO and go to this link: https://twitter.com/i/spaces/1mrGmanekZQGy
  • To ask questions during the Q&A, participants must join the Twitter Space using a mobile device
  • To listen only, participants can access the Twitter Space from a computer

 

RCI Hospitality will also be holding a Meet Management event that evening in Miami:

  • Investors are invited to meet management at RCI’s top revenue generating club
  • May 9th, at 8 PM ET, at Tootsie’s Cabaret Miami, 150 NW 183rd St., Miami, FL 33169
  • RSVP your contact information to gary.fishman@anreder.com

 

Stay up to date. Follow us:

 

Release – Gevo Reports First Quarter 2022 Financial Results



Gevo Reports First Quarter 2022 Financial Results

Research, News, and Market Data on Gevo

Gevo to Host Conference Call Today at 4:30 p.m. EST/2:30 p.m. MST

ENGLEWOOD, Colo.
May 9, 2022
– Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the first quarter of 2022 and recent corporate highlights.

Recent Corporate Highlights

  • On January 31, 2022, Gevo announced that it had begun the process of bringing its dairy manure-based renewable natural gas (“RNG”) project online in northwest Iowa and once this facility has reached steady-state production levels of approximately 355,000 MMBTU, its evaluation period by the California Air Resource Board and the Environmental Protection Agency for Low Carbon Fuel Standard (“LCFS”) and Renewable Identification Number (“RIN”) credits will commence.
  • Our Net-Zero 1 project continues to be on schedule, and we recently received the conditional use permits for the plant and the wind turbines that will help power the project.
  • Verity Tracking continues to develop a proprietary platform based on distributed ledger technology (also known as the “blockchain”) and recently partnered with Farmers’ Edge, a company dedicated to helping farmers track data and improve agricultural decision making, to support development.
  • On March 18, 2022, Gevo signed a “take-or-pay” agreement with British Airways plc to supply 30 million gallons per year of sustainable aviation fuel (“SAF”) over a five-year term.
  • On March 21, 2022, the oneworld® Alliance announced that certain of its members plan to purchase up to 200 million gallons per year of SAF from Gevo over a five-year term expected to commence in 2027.
  • On March 22, 2022, Gevo signed a “take-or-pay” agreement with Delta Air Lines, Inc. to supply 75 million gallons per year of SAF for seven years, replacing the existing agreement signed with Delta in 2019 to purchase 10 million gallons per year.

2022 First Quarter Financial Highlights

  • Ended the quarter with cash, cash equivalents, restricted cash and marketable securities of $429.6 million compared to $475.8 million as of the end of Q4 2021
  • Revenue of $0.2 million for the quarter compared to $0.1 million in Q1 2021
  • Loss from operations of $(16.0) million for the quarter compared to $(9.9) million in Q1 2021
  • Non-GAAP cash EBITDA loss of $(10.3) million for the quarter compared to $(7.8) million in Q1 2021
  • GAAP net loss per share and non-GAAP adjusted net loss per share of $(0.08) for the quarter compared to $(0.05) in Q1 2021

 

Commenting on the first quarter of 2022 and recent corporate events, Dr. Patrick R. Gruber, Gevo’s Chief Executive Officer, said “We are moving forward with our Net Zero 1 plans in Lake Preston, South Dakota and couldn’t be more pleased with the progress we have made. We look forward to beginning site preparations later this year and construction early next year. We believe we have a world class team in place to manage the development of this first of its kind, Net-Zero plant and the many additional plants that will be needed to produce this valuable fuel. In northwest Iowa, our dairy RNG facility continues its ramp to stable production and I am very proud of how well that team executed to deliver the project on time and within budget. We intend to build many Net-Zero plants over the coming years and we believe we have all the right people in place to get it done.”

 

First Quarter 2022 Financial Results

During the three months ended March 31, 2022, total revenue was $0.2 million, compared with $0.1 million in the same period in 2021. We sold approximately 35,000 gallons of SAF, isooctane and isooctene from our development facility at Luverne, Minnesota  in first quarter of 2022 compared to nil for the three months ended March 31, 2021 due to the COVID-19 shutdown.

Cost of goods sold was $4.2 million for the three months ended March 31, 2022, compared with $2.0 million in the same period in 2021. The majority of first quarter 2022 cost of goods sold was related to a $2.9 million adjustment made to the Company’s finished goods and work in process inventory to net realizable value with the offset recorded in cost of goods sold.

Selling, general and administrative expense increased by $5.6 million during the three months ended March 31, 2022, compared with the same period in 2021, due primarily to increases in personnel costs related to strategic new hiring, stock-based compensation, professional fees related to new contracts and higher costs for insurance.

Preliminary stage project costs are related to our NW Iowa RNG and Net-Zero projects and consist primarily of research and development expense in addition to selling, general and administrative expenses of the projects. Preliminary stage project costs decreased by $2.2 million during the three months ended March 31, 2022, compared to the same period in 2021. The decrease is primarily due to the capitalization of Net-Zero 1 project costs in the third quarter of 2021, after completing certain project milestones. Net-Zero 1 related costs and RNG related costs were still being expensed in the first quarter of 2021.

Gevo incurred a net loss for the three months ended March 31, 2022, of $(15.7) million, compared with a net loss of $(10.1) million during the same period in 2021. Non-GAAP adjusted net loss for the three months ended March 31, 2022, was $(15.7) million, compared with a non-GAAP adjusted net loss of $(10.0) million during the same period in 2021. Among other things, we incurred costs related to our production of isobutanol and hydrocarbon products for market development purposes, process technology and related process engineering work, expenses for additional intellectual property and know-how development for chemical and biological catalysts and related technologies, market development, partnership development, site development work, and Verity Tracking development expenses.

Non-GAAP cash EBITDA loss in the three months ended March 31, 2022, was $(10.3) million, compared with a $(7.8) million non-GAAP cash EBITDA loss in the same period in 2021.

During the three months ended March 31, 2022, we used $7.9 million in cash for investing activities, of which $71.1 million related to proceeds from sales and maturities of marketable securities, offset by the reinvestment of $31.2 million in marketable securities, and $31.5 million of investments in our capital projects, including $18.3 million in the NW Iowa RNG project, $9.6 million in the Net-Zero 1 project, as well as $3.2 million in development projects at Agri-Energy and Gevo.

 

Webcast and Conference Call Information

Hosting today’s conference call at 4:30 p.m. EST (2:30 p.m. MST) will be Dr. Patrick R. Gruber, Chief Executive Officer, L. Lynn Smull, Chief Financial Officer, Dr. Chris Ryan, Chief Operating Officer, Heather Manuel, Vice President – Investor Relations & Communications and John Richardson, Director of Investor Relations. They will review Gevo’s financial results and provide an update on recent corporate highlights

.

To participate in the conference call, please dial 1 (833) 729-4776 (inside the U.S.) or 1 (830) 213-7701 (outside the U.S.) and reference the access code 2251249# or through the event weblink https://edge.media-server.com/mmc/p/rkzfqmut

A replay of the call and webcast will be available two hours after the conference call ends on May 9, 2022. To access the replay, please dial 1 (855) 859-2056 (inside the U.S.) or 1 (404) 537-3406 (outside the U.S.) and reference the access code 2251249#. The archived webcast will be available in the Investor Relations section of Gevo’s website at www.gevo.com.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel, and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full lifecycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented, technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low carbon products such as gasoline components, jet fuel, and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that Argonne National Laboratory GREET model is the best available standard of scientific based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, our financial condition, our results of operation and liquidity, our business development activities, our Net-Zero Projects, our RNG Project, the engineering and design work for our projects, our offtake agreements, our plans to develop its business, our ability to successfully construct and finance our operations and growth projects, our ability to achieve cash flow from our planned projects, the ability of our products to contribute to lower greenhouse gas emissions, particulate and sulfur pollution, Verity Tracking development progress, project development costs and other statements that are not purely statements of historical fact These forward-looking statements are made based on the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2021 and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

 

 

Non-GAAP Financial Information

This press release contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), including non-GAAP cash EBITDA loss, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share. Non-GAAP cash EBITDA loss excludes depreciation and amortization and non-cash stock-based compensation from GAAP loss from operations. Non-GAAP adjusted net loss and adjusted net loss per share exclude non-cash gains and/or losses recognized in the quarter due to the changes in the fair value of certain of Gevo’s financial instruments, such as warrants, convertible debt and embedded derivatives, from GAAP net loss. Management believes these measures are useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information internally for its operating, budgeting and financial planning purposes. These non-GAAP financial measures also facilitate management’s internal comparisons to Gevo’s historical performance as well as comparisons to the operating results of other companies. In addition, Gevo believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management as a basis for its financial and operational decision making. Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under U.S. GAAP when understanding Gevo’s operating performance. A reconciliation between GAAP and non-GAAP financial information is provided in the financial statement tables below

 

Gevo, Inc.

Condensed Consolidated Balance Sheets Information

(Unaudited, in thousands, except share and per share
amounts)

March 31, 2022

December 31, 2021

Assets

Current assets

Cash and cash equivalents

$                     44,626

$                     40,833

Marketable securities (current)

                     265,813

                     275,340

Restricted cash (current)

                       16,216

                       25,032

Accounts receivable, net

                           168

                           978

Inventories

                         2,735

                         2,751

Prepaid expenses and other current assets

                         5,861

                         6,857

Total current assets

                     335,419

                     351,791

Property, plant and equipment, net

                     156,896

                     139,141

Long-term marketable securities

                       32,724

                       64,396

Long-term restricted cash

                       70,238

                       70,168

Operating right-of-use assets

                         2,209

                         2,414

Finance right-of-use assets

                       26,887

                       27,297

Intangible assets, net

                         8,656

                         8,938

Deposits and other assets

                         5,631

                         2,331

Total assets

$                   638,660

$                   666,476

Liabilities

Current liabilities

Accounts payable and accrued liabilities

$                     13,410

$                     28,288

Operating lease liabilities (current)

                           416

                           772

Finance lease liabilities (current)

                         4,029

                         3,413

Loans payable – other (current)

                             89

                           158

Total current liabilities

                       17,944

                       32,631

2021 Bonds payable (long-term)

                       66,669

                       66,486

Loans payable – other (long-term)

                           276

                           318

Operating lease liabilities (long-term)

                         1,838

                         1,902

Finance lease liabilities (long-term)

                       17,403

                       17,797

Other long-term liabilities

                             95

                             87

Total liabilities

                     104,225

                     119,221

Stockholders’ Equity

Common stock, $0.01 par value per share; 500,000,000 authorized; 201,752,722 and 201,988,662 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively.

                         2,019

                         2,020

Additional paid-in capital

                  1,107,051

                  1,103,224

Accumulated other comprehensive loss

                       (1,587)

                          (614)

Accumulated deficit

                    (573,048)

                    (557,375)

Total stockholders’ equity

                     534,435

                     547,255

Total liabilities and stockholders’ equity

$                   638,660

$                   666,476

 

Gevo, Inc.

Condensed Consolidated Statements of Operations
Information

(Unaudited, in thousands, except share and per share
amounts)

Three Months Ended March 31,

2022

2021

Revenue and cost of goods sold

Ethanol sales and related products, net

$                        169

$                          —

Hydrocarbon revenue

                            63

                            13

Other revenue

                            —

                            80

Total revenues

                          232

                            93

Cost of production

                       3,090

                          901

Depreciation and amortization

                       1,091

                       1,093

Gross loss

                     (3,949)

                     (1,901)

Operating expenses

Research and development expense (including noncash compensation expense of $0.1 million and $0.5 million, respectively)

                       1,192

                       1,378

Selling, general and administrative expense (including noncash compensation expense of $1.4 million and $0.5 million, respectively)

                       9,367

                       3,814

Preliminary stage project costs

                          507

                       2,727

Other operations (including noncash compensation expense of $0.1 million and nil, respectively)

                          589

                            —

Depreciation and amortization

                          351

                            58

Total operating expenses

                    12,006

                       7,977

Loss from operations

                   (15,955)

                     (9,878)

Other income (expense)

(Loss) gain from change in fair value of derivative warrant liability

                            —

                           (53)

Interest expense

                             (2)

                             (5)

Interest and dividend income

                          252

                            31

Other income (expense), net

                            32

                         (152)

Total other income (expense), net

                          282

                         (179)

Net loss

$                 (15,673)

$                 (10,057)

Net loss per share – basic and diluted

$                     (0.08)

$                     (0.05)

Weighted-average number of common shares outstanding – basic and diluted

201,925,747

183,566,524

 

Gevo, Inc.

Condensed Consolidated Statements of Comprehensive Income

(Unaudited, in thousands, except share and per share
amounts)

Three Months Ended March 31,

2022

2021

Net loss

$                 (15,673)

$                (10,057)

Other comprehensive income (loss)

Unrealized gain (loss) on available-for-sale securities, net of tax

                         (974)

                            —

Adjustment for net gain (loss) realized and included in net income, net of tax

                              1

                            —

Total change in other comprehensive income (loss)

                         (973)

                            —

Comprehensive loss

$                 (16,646)

$                (10,057)

 

Gevo, Inc.

Condensed Consolidated Statements of Stockholders Equity Information

(Unaudited, in thousands, except share amounts)

Common Stock

Paid-In Capital

Accumulated Other Comprehensive
Loss

Accumulated Deficit

Stockholders’ Equity

Shares

Balance, December 31, 2021

201,988,662

$     2,020

$    1,103,224

$                      (614)

$             (557,375)

$             547,255

Issuance of common stock upon exercise of warrants

4,677

            —

                  3

                          —

                      —

                         3

Non-cash stock-based compensation

            —

            4,044

                          —

                      —

                  4,044

Issuance of common stock under stock plans, net of taxes

(240,617)

            (1)

              (220)

                          —

                      —

                    (221)

Other comprehensive loss

            —

                —

                        (973)

                      —

                    (973)

Net loss

            —

                —

                          —

               (15,673)

               (15,673)

Balance, March 31, 2022

201,752,722

$     2,019

$    1,107,051

$                   (1,587)

$             (573,048)

$             534,435

Balance, December 31, 2020

128,138,311

$     1,282

$      643,269

$                        —

$             (498,172)

$             146,379

Issuance of common stock, net of issuance costs

68,170,579

          682

        457,008

                          —

                      —

               457,690

Issuance of common stock upon exercise of warrants

1,863,058

            18

            1,099

                          —

                      —

                  1,117

Non-cash stock-based compensation

            —

               562

                          —

                      —

                     562

Issuance of common stock under stock plans, net of taxes

(121,499)

            (1)

                  1

                          —

                      —

                       —

Net loss

            —

                —

                          —

               (10,057)

               (10,057)

Balance, March 31, 2021

198,050,449

$     1,981

$    1,101,939

$                        —

$             (508,229)

$             595,691

 

Gevo, Inc.

Condensed Consolidated Cash Flow Information

(Unaudited, in thousands)

Three Months Ended March 31,

2022

2021

Operating Activities

Net loss

$                    (15,673)

$                   (10,057)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation

                         4,258

                           925

Depreciation and amortization

                         1,442

                        1,149

Non-cash lease expense

                            139

                             17

Non-cash interest expense

                         1,150

                             —

Changes in operating assets and liabilities:

Accounts receivable

                            810

                           435

Inventories

                             16

                             39

Prepaid expenses and other current assets, deposits and other assets

                        (2,317)

                       (4,273)

Accounts payable, accrued expenses and long-term liabilities

                        (2,285)

                        4,600

Net cash used in operating
activities

                      (12,460)

                       (7,165)

Investing Activities

Acquisitions of property, plant and equipment

                      (31,218)

                       (4,630)

Acquisition of patent portfolio

                            (10)

                             —

Proceeds from sale and maturity of marketable securities

                       71,082

                             —

Purchase of marketable securities

                      (31,993)

                             —

Net cash used in investing
activities

                         7,861

                       (4,630)

Financing Activities

Debt and equity offering costs

                             —

                     (31,683)

Proceeds from issuance of common stock and common stock warrants

                             —

                     489,373

Proceeds from exercise of warrants

                               3

                        1,117

Net settlement of common stock under stock plans

                          (220)

                             —

Payment of loans payable – other

                          (103)

                            (27)

Payment of finance lease liabilities

                            (34)

                             —

Net cash provided by financing
activities

                          (354)

                     458,780

Net increase (decrease) in cash
and cash equivalents

                        (4,953)

                     446,985

Cash, cash equivalents and restricted cash at beginning of period

136,033

78,338

Cash, cash equivalents and
restricted cash at end of period

$                   131,080

$                   525,323

 

Gevo, Inc.

Reconciliation of GAAP to Non-GAAP Financial Information

(Unaudited, in thousands, except share and per share
amounts)

Three Months Ended March 31,

2022

2021

Non-GAAP Cash EBITDA:

Loss from operations

$                 (15,955)

$                   (9,878)

Depreciation and amortization

                       1,442

                       1,149

Stock-based compensation

                       4,258

                          925

Non-GAAP cash EBITDA

$                 (10,255)

$                   (7,804)

Non-GAAP Adjusted Net Loss:

 

 

Net Loss

$                 (15,673)

$                 (10,057)

Adjustments:

Gain (loss) from change in fair value of derivative warrant liability

                             —

                           (53)

Total adjustments

                            —

                           (53)

Non-GAAP Net Income (Loss)

$                 (15,673)

$                 (10,004)

Non-GAAP adjusted net loss per share – basic and diluted

$                     (0.08)

$                     (0.05)

Weighted-average number of common shares outstanding – basic and diluted

201,925,747

183,566,524

Investor and Media Contact

+1 720-647-9605

IR@gevo.com

1 Cash EBITDA loss
is a non-GAAP measure calculated by adding back depreciation and amortization
and non-cash stock-based compensation to GAAP loss from operations. A
reconciliation of cash EBITDA loss to GAAP loss from operations is provided
in the financial statement tables following this release.

2 Adjusted net
loss per share is a non-GAAP measure calculated by adding back non-cash gains
and/or losses recognized in the quarter due to the changes in the fair value
of certain of our financial instruments, such as warrants, convertible debt
and embedded derivatives, to GAAP net loss per share. A reconciliation of
adjusted net loss per share to GAAP net loss per share is provided in the
financial statement tables following this release.

3 Adjusted net
loss is a non-GAAP measure calculated by adding back non-cash gains and/or
losses recognized in the quarter due to the changes in the fair value of
certain of our financial instruments, such as warrants, convertible debt and
embedded derivatives, to GAAP net loss. A reconciliation of adjusted net loss
to GAAP net loss is provided in the financial statement tables following this
release.

4 Cash EBITDA loss
is a non-GAAP measure calculated by adding back depreciation and amortization
and non-cash stock compensation to GAAP loss from operations. A
reconciliation of cash EBITDA loss to GAAP loss from operations is provided
in the financial statement tables following this release.

 

Investor & Media Contact:

Gevo Inc.
345 Inverness Drive South, Building C Suite 310,
Englewood, CO 80112
Phone: +1 720-647-9605
Email: IR@gevo.com

Diamond Supply Pressures Could Benefit Public Mining Companies


Image Credit: Kim Alaniz (Flickr)


Will Reduced Diamond Production in Europe Bode Well for Producers Elsewhere?

They say that if the economy is faltering that you should invest in hard assets, or companies that produce them. Hard asset investing can include commodities like gold, silver, and platinum with value extending to equities of producers of these durable metals. It may also include collectibles like fine art and diamonds and other gemstones. In the case of diamonds, the axiom extends to producers (mining companies) as well.

Diamond Supply Side Down

Demand for diamonds did not dip during the pandemic, sales just moved from brick and mortar to online purchases. So the pace remained consistent, which is usuall at about the same pace they are consumed. Diamonds are scarce, so by definition, supply is typically tight. But, the recent Russia/Ukraine issues have had an impact since 30-35% of the worlds diamonds that once were sold out of Russia are off now limits. 


Diamond Price Index (DPI) provided by diamondse.info, June 2009 – May 2022

Taking up the Slack

With demand remaining consistent at 130 million carats per year and supply being significantly pinched, those able to supply diamonds stand to fare much better than other years since the unmet need for diamonds from non-conflict areas is likely to be much stronger as a result.

When people in North America think of diamond mining, they usually think of South Africa, not Europe. The impact of what is going on in Europe is not interrupting operations in South Africa’s ability to add new diamonds to market.

One junior diamond mining company which has a well-established prior operational and production history in South Africa, extensive prior experience supplying rough diamonds to the world market, and a long-established alliance with Tiffany & Co., DeBeers, and others is Diamcor Mining Inc. (DMIFF,
DMI:CA
).

Diamcor’s focus is on idetification, acquisition, and operation of diamond projects with near term production potential. This allows this company to avoid the high risks and costs associated with traditional exploration.

In a video from the recent NobleCon18, Dean Taylor, CEO of Diamcor Mining discussed that his company is production-focused, bringing supply of raw diamonds to sellers. In addition to having a strategic alliance with Tiffany’s the retailer is also a shareholder of the company.

To gain deeper understanding of the supply factors impacting world diamond production and partnerships, as well as Diamcor’s business specifically and value, watch the video here

Take-Away

As we have seen with other industries that impact our everyday life at the grocery store, gas stations, and elsewhere, geopolitical events have an effect on prices and company earnings. Diamonds and gemstones are not what is being discussed when we chat over the fence with our neighbors, but this may mean that the opportunities have not yet been recognized by the investing masses.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Exposure to Non-Travel Leisure Stocks



Can Energy Stocks Continue Their High Octane Performance?




Energy and Global Fundamentals Make a Good Case for Owning Western Uranium Stocks



Diamcor Mining (DMIFF) NobleCon18 Presentation Replay

Sources

https://www.aljazeera.com/economy/2022/5/9/angolas-endiama-says-sanctions-against-russia-could-hurt-its-diamond-operations

http://www.diamcormining.com/investors/diamond-information/

https://www.diamondse.info/diamonds-price-index.asp

 

Stay up to date. Follow us:

 

Release – Schwazze to Host First Quarter Conference Call and Webcast May 16, 2022



Schwazze to Host First Quarter Conference Call and Webcast May 16, 2022

Research, News, and Market Data on Schwazze

DENVER, May 9, 2022 /CNW/ – Schwazze, (OTCQX: SHWZ) (NEO:SHWZ) (“Schwazze” or the “Company”), announces that it will host a first quarter 2022 conference call and webcast on May 16, 2022 at 4:30 pm EDT.

 

Investors and stakeholders may participate in the conference call by dialing 416 764 8650 or by dialing North American toll free 888-664-6383 or listen to the webcast from the Company’s website at https://ir.schwazze.com. The webcast will be available on the Company’s website and on replay until May 23, 2022, and may be accessed by dialing 888-390-0541 / 117902#.

Following their prepared remarks, Chief Executive Officer, Justin Dye and Chief Financial Officer, Nancy Huber will answer investor questions. Investors may submit questions in advance or during the conference call itself through the weblink: https://produceredition.webcasts.com/starthere.jsp?ei=1548621&tp_key=88d9ed2417  This weblink has been posted to the Company’s website and will be archived on the website. All Company SEC filings can also be accessed on the Company website at https://ir.schwazze.com/sec-filings  and on SEDAR at www.sedar.com  

About Schwazze

Schwazze (OTCQX: SHWZ; NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high- performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices. Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “estimates”, “predicts,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses and realize synergies therefrom, (ix) the actual revenues derived from the Company’s Star Buds assets, * the Company’s actual revenue and adjusted EBITDA for 2021, (xi) the Company’s ability to generate positive cash flow for the rest of 2021 (xii) the ongoing COVID-19 pandemic, (xiii) the timing and extent of governmental stimulus programs, and (xiv) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/schwazze-to-host-first-quarter-conference-call–webcast-may-16-2022-301542234.html

SOURCE Medicine Man Technologies, Inc.

Release – Eagle Bulk Shipping Inc. Publishes 2022 ESG Sustainability Report



Eagle Bulk Shipping Inc. Publishes 2022 ESG Sustainability Report

Research, News, and Market Data on Eagle Bulk Shipping

STAMFORD, Conn., May 09, 2022 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (Nasdaq: EGLE) (“Eagle Bulk”, “Eagle”, or the “Company”), one of the world’s largest owner-operators within the midsize drybulk segment, today announced the publication of its third annual Environmental, Social, and Governance (ESG) Sustainability Report.

The report, which has been prepared in accordance with the Marine Transportation Framework established by the Sustainability Accounting Standards Board (SASB), provides an overview of Eagle’s strategic priorities and performance with respect to various environmental, social, and governance-related matters.

Gary Vogel, Eagle Bulk’s CEO, commented, “Eagle Bulk advanced a number of important ESG-related initiatives in 2021, which are detailed in our report. We have embedded these initiatives across our company, as demonstrated by the sustainability-linked targets included in the new credit facility we entered into during the fourth quarter of 2021, which allow the Company to decrease its interest rate margin, subject to meeting fleet energy efficiency targets and making investments in decarbonization initiatives. I’m pleased to report that we have met these targets for 2021 and will benefit from a decrease in our margin starting this June, which will step down to 210 basis points over 3-month LIBOR.   Additionally, we improved our fuel efficiency profile by adding nine modern vessels to our fleet and completed our first ever sustainable biofuel voyage, sailing the M/V Sydney Eagle across the Atlantic and reducing the vessel’s net well-to-wake CO2 emissions by ~90% during the voyage.

From a Social perspective, our top priority has been to ensure the health and safety of our employees, both onshore and onboard our vessels. COVID-19 continued to impact our business in 2021. We have had some colleagues deal with illness personally, while others had to cater to family being impacted at home.

More recently, the tragic events taking place in Ukraine have significantly impacted our Ukrainian seafarers, and we are doing what we can to ensure their safety and well-being by providing assistance with temporary housing, transportation, and other needs.”

Eagle’s ESG Sustainability Report can be accessed on the Company’s website at www.eagleships.com/ESG.

CONTACT

Company Contact:
Frank De Costanzo
Chief Financial Officer
Eagle Bulk Shipping Inc.
Tel. +1 203-276-8100
Email: 
investor@eagleships.com

Media:
Rose and Company
Tel. +1 212-359-2228

Source: Eagle Bulk Shipping Inc.


History of Hawkish Fed Policy and Soft Landings


Image Credit: Jaime Robles (Flickr)


Fed Hopes for ‘Soft Landing’ for the US Economy, but History Suggests it Won’t be Able to Prevent a Recession

The Federal Reserve will likely soon learn what gymnasts already know: sticking a landing is hard.

With inflation surging to a new 40-year high and continuing to accelerate, the Fed is expected to again lift interest rates by a half-percentage point at the end of its next meeting. It will be the third of seven planned rate hikes in 2022 – following increases in March and May – as the Fed tries to cool consumer demand and slow rising prices.

By raising interest rates, the central bank is hoping to achieve a proverbial “soft landing” for the U.S. economy, in which it’s able to tame rapid inflation without causing unemployment to rise or triggering a recession. The Fed and professional forecasters project that inflation will recede to below 3% and unemployment will remain under 4% in 2023.

Our recent research, however, suggests that engineering a soft landing is highly improbable and that there is a significant likelihood of a recession in the not too distant future.

That’s because high inflation and low unemployment are both strong predictors of future recessions. In fact, since the 1950s, every time inflation has exceeded 4% and unemployment has been below 5%, the U.S. economy has gone into a recession within two years.

Today, inflation is at 8.5% and unemployment is at 3.6% – suggesting a recession will be very hard to avert.

Behind the Curve

Inflation is fundamentally caused by too much money chasing too few goods.

In the short run, the supply of goods in the economy is more or less fixed – there is nothing that fiscal or monetary policy can do to change it – so the job of the Fed is to manage total demand in the economy so that it balances with the available supply.

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It was written by and represents the research-based opinions of Alex Domash, Research Fellow, Harvard Kennedy School, and Lawrence H. Summers, Charles W. Eliot University Professor, Harvard Kennedy School.

When demand runs too far ahead of supply, the economy begins to overheat, and prices rise sharply. In our assessment, measures of overheating – such as strong demand growth, diminishing inventories and rising wages – began to show in the economy throughout 2021. But a new operating framework that the Fed adopted in August 2020 prevented the Fed from taking action until sustained inflation was already apparent.

As a result, the Fed is way behind the curve today in responding to an overheating economy.

Sticking a Soft Landing
is Hard

To bring down surging inflation, the Fed will now try to raise interest rates to curb consumer demand.

The resulting increase in borrowing costs can help slow economic activity by discouraging consumers and businesses from making new investments. But it would come at the risk of causing major economic disruptions and pushing the economy into a recession. This is the soft landing: Interest rates rise and demand falls enough to lower inflation, but the economy keeps growing.

The history of engineering soft landings is not encouraging, however. We found that every time the Fed has hit the brakes hard enough to bring down inflation in a meaningful way, the economy has gone into recession.

While some have argued that there have been several examples of soft landings over the last 60 years, including in 1965, 1984 and 1994, we show in our analysis that these periods had little resemblance to the current moment.

In all three episodes, the Fed was operating in an economy with significantly higher unemployment, lower inflation and lower wage growth. In these historical examples, the Fed also raised interest rates well above the inflation rate – unlike today, where inflation is at 8.5% and interest rates are projected to remain below 3% through 2023 – and explicitly acted early to preempt inflation from spiraling, rather than waiting for inflation to already be excessive.

Why is the Labor Market
Relevant for Inflation?

One reason the Fed’s challenge is particularly difficult today is that the labor market is unprecedentedly tight, meaning the demand for workers is far outpacing the available supply of them. A tight labor market implies that companies need to raise wages to attract new workers.

Usually, the unemployment rate is used as an indicator for labor market tightness. Unemployment is very low today, and the Fed expects it to go even lower. But our research shows that the pressure to raise wages is even higher than indicated by the unemployment rate. The number of job openings are at all an all-time high, and workers are quitting at record rates – both of which are significant for driving up wages.

In a sense, wages are the ultimate measure of core inflation – more than two-thirds of business costs go back to labor – so rising wages put significant upward pressure on inflation. Wage growth today is running at a historic rate of 6.6% and accelerating.

With wages rising so fast, there is little basis for optimism that inflation can slow to the 2% range targeted by the Fed. Our analysis shows that current wage growth implies sustained inflation above 5%, and that historically wage growth does not slow without significant increases in unemployment and a recession.

The U.S. economy today is facing additional inflationary pressures from higher grain and energy prices due to the Ukraine war and more supply-chain disruptions as COVID-19 forces new lockdowns in China. These factors threaten to exacerbate inflation even more over the coming year.

In our assessment, the inflation problem facing the Fed today is substantial and unlikely to be resolved without a significant economic slowdown. Overall, the combination of an overheating economy, surging wages, policy delay by the Fed and recent supply shocks means that a recession in the next couple of years is certainly more likely than not.


Suggested Reading



Can the Fed Successfully do What Has Never Been Done Before?



The Detrimental Impact of Fed Policy on Savers





Will Investors Rework their Positions in Response to Fed Statements?



Did the Stock Market Already Overshoot to the Downside in 2022?

 

Stay up to date. Follow us:

 

Baudax Bio (BXRX) – First Quarter 2022 Reported; Slow But Steady Progress

Friday, May 06, 2022

Baudax Bio (BXRX)
First Quarter 2022 Reported; Slow But Steady Progress

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q 2022 revenues reported. Late Wednesday the 4th, Baudax Bio released their 1Q 2022 results and held a conference call early on the 5th.  Revenues of $.422 million, somewhat due to timing differences, missed our estimate of $.577 million.  Covid still muted Q1 procedures, but procedure growth showed signs of life late in the quarter.

Company reduced headcount and expenses. In March, the Company implemented a reduction in force (RIF) workplace plan to curtail expenses and reduce need for capital. Intended to reduce operating costs in connection with ANJESO commercialization, the company expects approximately $4.0 million in severance and related costs to be taken by end of 2Q 2022, of which approximately $1.7 million was taken late in Q1. Cash burn will be substantially reduced in 2H 2022 and beyond. The company is evaluating possible partnering options which will further reduce cash needs.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alvopetro Energy (ALVOF) – April production levels remain on target

Friday, May 06, 2022

Alvopetro Energy (ALVOF)
April production levels remain on target

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Alvopetro reported April sales volumes of 2,494 barrel of oil equivalent per day (boepd). Results were slightly below March sales volumes of 2,512 boepd and March quarter levels of 2,501 boepd reflecting natural well production declines. Results were slightly above the 2,461 boepd rate we have modeled for the June quarter. The completion of the 182-C1 well in March and the expected completion of the 183-B1 well in May should offset normal well declines and boost overall production going forward.

Alvopetro anticipates announcing 2022-1Q results after market close on May 12th. Management will host a call with investors on May 13th at 10:00 EST. We are expecting revenues of $13.3 million, a 110% annual and 45% sequential increase due mainly to an increase in the price of gas received. We look for EBITDA of $11 million and earnings of $5.9 million ($0.17 per share)….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.